SheMed Raises 43 Million Euros to Improve Women's Healthcare

• London-based women's HealthTech firm SheMed raised €43 million
• The firm will enhance healthcare services, technology, and the use of data
• Objective is more personalised and preventive health for women

SheMed, the female-founded HealthTech firm in London, has raised €43 million to further build its health platform and drive preventive healthcare for women.

The capital will be used to grow SheMed's operations in the UK, including increasing its medical and tech teams, enhancing clinical infrastructure, and the development of data-driven capabilities.

CEO and co-founder Olivia Ferro pointed out that SheMed was designed to offer women personalized healthcare assistance, based on her own experience with a GLP-1 condition.

President and co-founder Chloe Ferro identified high demand for services acknowledging individual health requirements and experiences.

Established in April 2024 by sisters Olivia and Chloe, SheMed has rapidly become a top provider of tailored women's healthcare, combining medical supervision, wellness monitoring, and 24/7 support via its online platform.

The firm has onboarded more than 60,000 members within a year and runs the UK's fastest-growing GLP-1 and weight-management program.

The new investment is part of wider trends in UK and European HealthTech investment in women's and preventive care.

Other UK-based startups in similar fields, including Numan and Hormona, have also raised considerable capital this year, as investors increasingly target personalised and data-driven health solutions.

The investment will also be used to fund research and innovation to enhance patient experience and access to personalized care.

Towards the end of this month, SheMed is set to publish the results of the first ever female-specific GLP-1 clinical study, providing insights into how these drugs impact women's hormonal and metabolic responses and guiding future treatment strategies.